First Access


Recommends 6-8 small and microcap stocks annually, mostly in biotech, with weekly updates and conference calls with management of the companies they pick.

Related Gumshoe Articles

Leave a Reply

3 Comments on "First Access"

avatar

don johnson
Guest
0
don johnson
April 13, 2010 3:30 pm

i think if a listing of co’s and dates of fda info releases were known we could all be millionaires with a few good guesses!! what a lottery this is!!

Jeff  Abbott
Guest
0
Jeff Abbott
April 14, 2010 6:30 pm
Don’t know anything about this newsletter but i can tell you that Sangamo is the real deal in terms of a quality Biotech, quality science with a unique and impressive platform(zinc finger). It is a highly recommended and followed small cap developmental biotech with an impressive pipeline. That being said no matter how impressive the science, trial stages are always a crapshoot, especially the more advanced that are. I follow this company and it’s science fairly closely and my opinion is that they will show positive,significant results in their IIB results but i do not think it will be worth… Read more »
R. M. Kribs
Guest
0
R. M. Kribs
April 24, 2010 4:03 pm

I have never had First Access, but have been stung by Marc Lichtenfeld when he wrote about Accuray (ARAY) for Xcelerated Profits. I was supposed to get a 119% return, but got a loss instead–& don`t know why. ARAY has a unique product in it`s Cyberknife, so should be worth more than $6-$7. Therefore, something must be wrong with management & as a Senior Analyst (?) Marc should have known that.

wpDiscuz